Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.
Nagot N, Kankasa C, Meda N, Hofmeyr J, Nikodem C, Tumwine JK, Karamagi C, Sommerfelt H, Neveu D, Tylleskär T, Van de Perre P; PROMISE-PEP group. Nagot N, et al. Among authors: tylleskar t. BMC Infect Dis. 2012 Oct 6;12:246. doi: 10.1186/1471-2334-12-246. BMC Infect Dis. 2012. PMID: 23039034 Free PMC article. Clinical Trial.
HIV-1 disease progression in immune-competent HIV-1-infected and breastfeeding mothers participating in the ANRS 12174 clinical trial in Burkina Faso, South Africa, Uganda and Zambia: a cohort study.
Somé EN, Engebretsen IMS, Nagot N, Meda NY, Vallo R, Kankasa C, Tumwine JK, Singata-Madliki M, Harper K, Hofmeyr GJ, Van de Perre P, Tylleskär T; ANRS 12174 Trial Group. Somé EN, et al. Among authors: tylleskar t. BMJ Open. 2018 Apr 5;8(4):e019239. doi: 10.1136/bmjopen-2017-019239. BMJ Open. 2018. PMID: 29626043 Free PMC article. Clinical Trial.
Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.
Blanche S, Tylleskär T, Peries M, Kankasa C, Engebretsen I, Meda N, Tumwine JK, Singata-Madliki M, Mwiya M, Van de Perre P, Nagot N; ANRS 12174 Trial Group. Blanche S, et al. Among authors: tylleskar t. Lancet HIV. 2019 May;6(5):e307-e314. doi: 10.1016/S2352-3018(18)30361-8. Epub 2019 Feb 24. Lancet HIV. 2019. PMID: 30814028 Clinical Trial.
Lopinavir-Ritonavir Impairs Adrenal Function in Infants.
Kariyawasam D, Peries M, Foissac F, Eymard-Duvernay S, Tylleskär T, Singata-Madliki M, Kankasa C, Meda N, Tumwine J, Mwiya M, Engebretsen I, Flück CE, Hartmann MF, Wudy SA, Hirt D, Treluyer JM, Molès JP, Blanche S, Van De Perre P, Polak M, Nagot N; ANRS 12174 Trial Group. Kariyawasam D, et al. Among authors: tylleskar t. Clin Infect Dis. 2020 Aug 14;71(4):1030-1039. doi: 10.1093/cid/ciz888. Clin Infect Dis. 2020. PMID: 31633158 Free article.
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life.
Nagot N, Singata-Madliki M, Cournil A, Nalugya J, Tassembedo S, Quillet C, Tonga MW, Tumwine J, Meda N, Kankasa C, Mwiya M, Bangirana P, Peries M, Batting J, Engebretsen IMS, Tylleskär T, Perre PV, Ndeezi G, Molès JP. Nagot N, et al. Among authors: tylleskar t. Sci Rep. 2021 Feb 4;11(1):3173. doi: 10.1038/s41598-021-82762-8. Sci Rep. 2021. PMID: 33542437 Free PMC article. Clinical Trial.
Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, Mwiya M, Kwagala M, Traore H, Sunday A, Singata M, Siuluta C, Some E, Rutagwera D, Neboua D, Ndeezi G, Jackson D, Maréchal V, Neveu D, Engebretsen IMS, Lombard C, Blanche S, Sommerfelt H, Rekacewicz C, Tylleskär T, Van de Perre P; ANRS 12174 Trial Group. Nagot N, et al. Among authors: tylleskar t. Lancet. 2016 Feb 6;387(10018):566-573. doi: 10.1016/S0140-6736(15)00984-8. Epub 2015 Nov 19. Lancet. 2016. PMID: 26603917 Clinical Trial.
Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.
Foissac F, Blume J, Tréluyer JM, Tylleskär T, Kankasa C, Meda N, Tumwine JK, Singata-Madliki M, Harper K, Illamola SM, Bouazza N, Nagot N, Van de Perre P, Blanche S, Hirt D. Foissac F, et al. Among authors: tylleskar t. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01869-16. doi: 10.1128/AAC.01869-16. Print 2017 Feb. Antimicrob Agents Chemother. 2017. PMID: 27895016 Free PMC article.
Changes in body mass index and hemoglobin concentration in breastfeeding women living with HIV with a CD4 count over 350: Results from 4 African countries (The ANRS 12174 trial).
Somé EN, Engebretsen IMS, Nagot N, Meda NY, Vallo R, Kankasa C, Tumwine JK, Singata M, Hofmeyr JG, Van de Perre P, Tylleskär T; ANRs 12174 Trial Group. Somé EN, et al. Among authors: tylleskar t. PLoS One. 2017 May 9;12(5):e0177259. doi: 10.1371/journal.pone.0177259. eCollection 2017. PLoS One. 2017. PMID: 28486519 Free PMC article. Clinical Trial.
239 results